TNXP Tonix Pharmaceuticals | $37.98
+5.9% | 2/28/2024 | - | Initiated Coverage | Buy | $9,600.00 | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 2/28/2024 |
DARE Dare Bioscience | $2.12
+1.0% | 1/30/2024 | J. Kolbert | Downgrade | Buy -> Neutral | | View details for Dawson James rating of Dare Bioscience (NASDAQ:DARE) on 1/30/2024 |
BYRN Byrna Technologies | $20.20
+5.2% | 9/27/2023 | - | Downgrade | Buy -> Neutral | | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 9/27/2023 |
THAR Tharimmune | $4.72
-5.0% | 7/17/2023 | J. Kolbert | Downgrade | Buy -> Neutral | | View details for Dawson James rating of Tharimmune (NASDAQ:THAR) on 7/17/2023 |
BYRN Byrna Technologies | $20.20
+5.2% | 7/12/2023 | - | Lower Price Target | | $9.50 -> $7.25 | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 7/12/2023 |
TOON Kartoon Studios | $0.75
+2.6% | 7/11/2023 | - | Lower Price Target | | $12.50 -> $10.00 | View details for Dawson James rating of Kartoon Studios (NASDAQ:TOON) on 7/11/2023 |
NRXP NRx Pharmaceuticals | $2.64
+4.3% | 3/17/2023 | J. Kolbert | Reiterated Rating | Buy | | View details for Dawson James rating of NRx Pharmaceuticals (NASDAQ:NRXP) on 3/17/2023 |
GOVX GeoVax Labs | $0.77
+2.7% | 3/3/2023 | - | Initiated Coverage | Buy | $60.00 | View details for Dawson James rating of GeoVax Labs (NASDAQ:GOVX) on 3/3/2023 |
THAR Tharimmune | $4.72
-5.0% | 2/22/2023 | J. Kolbert | Reiterated Rating | Buy | | View details for Dawson James rating of Tharimmune (NASDAQ:THAR) on 2/22/2023 |
SMSI Smith Micro Software | $0.70
+3.6% | 2/28/2023 | - | Lower Price Target | | $66.40 -> $28.00 | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 2/28/2023 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
BCDA BioCardia | $1.91
+5.5% | 11/11/2022 | J. Kolbert | Downgrade | Buy -> Neutral | | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 11/11/2022 |
BYRN Byrna Technologies | $20.20
+5.2% | 9/8/2022 | - | Lower Price Target | | $12.00 -> $9.50 | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 9/8/2022 |
PRPH ProPhase Labs | $0.33
-1.9% | 7/21/2022 | - | Downgrade | Neutral -> Sell | | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 7/21/2022 |
DYAI Dyadic International | $0.85
+8.8% | 7/18/2022 | J. Kolbert | Downgrade | Buy -> Neutral | | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 7/18/2022 |
KURA Kura Oncology | $7.65
+2.8% | 5/16/2022 | J. Kolbert | Downgrade | Buy -> Neutral | | View details for Dawson James rating of Kura Oncology (NASDAQ:KURA) on 5/16/2022 |
BYRN Byrna Technologies | $20.20
+5.2% | 4/26/2022 | - | Initiated Coverage | Buy | $12.00 | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 4/26/2022 |
LCTX Lineage Cell Therapeutics | $1.20
+2.6% | 3/11/2022 | Jason Kolbert | Reiterated Rating | Buy | $6.00 | View details for Dawson James rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 3/11/2022 |
SMSI Smith Micro Software | $0.70
+3.6% | 3/11/2022 | - | Lower Price Target | Buy | $91.20 -> $66.40 | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 3/11/2022 |
KNW Know Labs | $2.14
+3.8% | 2/8/2022 | - | Initiated Coverage | Buy | $280.00 | View details for Dawson James rating of Know Labs (NYSEAMERICAN:KNW) on 2/8/2022 |
VUZI Vuzix | $2.13
+11.5% | 12/21/2021 | - | Initiated Coverage | Buy | $15.00 | View details for Dawson James rating of Vuzix (NASDAQ:VUZI) on 12/21/2021 |
PRPH ProPhase Labs | $0.33
-1.9% | 10/13/2021 | J. Kolbert | Downgrade | Buy -> Neutral | | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 10/13/2021 |
SMSI Smith Micro Software | $0.70
+3.6% | 8/5/2021 | - | Initiated Coverage | Buy | $88.80 | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 8/5/2021 |
AVXL Anavex Life Sciences | $9.53
-0.2% | 6/21/2021 | - | Boost Price Target | Buy | $19.00 -> $35.00 | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 6/21/2021 |
BCDA BioCardia | $1.91
+5.5% | 4/22/2021 | J. Kolbert | Reiterated Rating | Buy -> Neutral | | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 4/22/2021 |
BCDA BioCardia | $1.91
+5.5% | 4/16/2021 | J. Kolbert | Downgrade | Buy -> Neutral | | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 4/16/2021 |
CTXR Citius Pharmaceuticals | $1.35
+9.8% | 2/25/2021 | J. Kolbert | Reiterated Rating | Buy | $150.00 | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 2/25/2021 |
FBIO Fortress Biotech | $2.27
+1.3% | 2/17/2021 | - | Boost Price Target | Buy | $240.00 -> $315.00 | View details for Dawson James rating of Fortress Biotech (NASDAQ:FBIO) on 2/17/2021 |
PRPH ProPhase Labs | $0.33
-1.9% | 1/20/2021 | - | Initiated Coverage | Buy | $25.00 | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 1/20/2021 |
LCTX Lineage Cell Therapeutics | $1.20
+2.6% | 10/12/2020 | - | Reiterated Rating | Buy | $6.00 | View details for Dawson James rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 10/12/2020 |
CTXR Citius Pharmaceuticals | $1.35
+9.8% | 9/17/2020 | J. Kolbert | Reiterated Rating | Buy | | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 9/17/2020 |
SNGX Soligenix | $3.38
+0.6% | 7/28/2020 | J. Kolbert | Downgrade | Buy -> Neutral | $48.00 -> $32.00 | View details for Dawson James rating of Soligenix (NASDAQ:SNGX) on 7/28/2020 |
DARE Dare Bioscience | $2.12
+1.0% | 7/12/2020 | - | Reiterated Rating | Buy | $36.00 | View details for Dawson James rating of Dare Bioscience (NASDAQ:DARE) on 7/12/2020 |
AVXL Anavex Life Sciences | $9.53
-0.2% | 6/8/2020 | - | Reiterated Rating | Buy | $16.00 | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 6/8/2020 |
CTSO Cytosorbents | $0.91
+8.2% | 3/9/2020 | - | Reiterated Rating | Buy | $15.00 -> $17.00 | View details for Dawson James rating of Cytosorbents (NASDAQ:CTSO) on 3/9/2020 |
DYAI Dyadic International | $0.85
+8.8% | 2/26/2020 | Jason Kolbert | Reiterated Rating | Buy | | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 2/26/2020 |
MESO Mesoblast | $15.81
+4.2% | 12/19/2019 | Jason Kolbert | Initiated Coverage | Buy | $28.00 | View details for Dawson James rating of Mesoblast (NASDAQ:MESO) on 12/19/2019 |
DYAI Dyadic International | $0.85
+8.8% | 10/16/2019 | - | Initiated Coverage | Buy | $14.00 | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 10/16/2019 |
BCDA BioCardia | $1.91
+5.5% | 9/17/2019 | Jason Kolbert | Initiated Coverage | Buy | $360.00 | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 9/17/2019 |
BCDA BioCardia | $1.91
+5.5% | 9/17/2019 | J. Kolbert | Reiterated Rating | Buy | | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 9/17/2019 |
CTXR Citius Pharmaceuticals | $1.35
+9.8% | 9/6/2019 | Jason Kolbert | Initiated Coverage | Buy | $175.00 | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 9/6/2019 |
Musk’s Project Colossus could mint millionaires (Ad) I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history.
And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. All the details are waiting for you now — but you need to act before the September 1st funding windo |
FBIO Fortress Biotech | $2.27
+1.3% | 8/26/2019 | - | Initiated Coverage | Buy | $285.00 | View details for Dawson James rating of Fortress Biotech (NASDAQ:FBIO) on 8/26/2019 |
ADMA ADMA Biologics | $17.80
+4.1% | 8/12/2019 | J. Kolbert | Downgrade | Buy -> Neutral | $4.00 | View details for Dawson James rating of ADMA Biologics (NASDAQ:ADMA) on 8/12/2019 |
AVXL Anavex Life Sciences | $9.53
-0.2% | 7/24/2019 | J. Kolbert | Initiated Coverage | Buy | $16.00 | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 7/24/2019 |
KURA Kura Oncology | $7.65
+2.8% | 7/11/2019 | J. Kolbert | Reiterated Rating | Buy | | View details for Dawson James rating of Kura Oncology (NASDAQ:KURA) on 7/11/2019 |
INTT inTEST | $7.00
+4.0% | 12/28/2018 | B. Sine | Reiterated Rating | Buy | | View details for Dawson James rating of inTEST (NYSE:INTT) on 12/28/2018 |
WYY WidePoint | $4.23
+12.5% | 12/3/2018 | B. Sine | Reiterated Rating | Buy | | View details for Dawson James rating of WidePoint (NYSEAMERICAN:WYY) on 12/3/2018 |
WTT Wireless Telecom Group | $2.13
| 12/3/2018 | B. Sine | Reiterated Rating | Buy | | View details for Dawson James rating of Wireless Telecom Group (NYSEAMERICAN:WTT) on 12/3/2018 |
CNVS Cineverse | $5.37
+11.6% | 10/22/2018 | B. Sine | Initiated Coverage | Buy | | View details for Dawson James rating of Cineverse (NASDAQ:CNVS) on 10/22/2018 |
FRX Fennec Pharmaceuticals | C$11.94
+4.3% | 10/10/2018 | C. Werther | Reiterated Rating | Buy | | View details for Dawson James rating of Fennec Pharmaceuticals (TSE:FRX) on 10/10/2018 |
FENC Adherex Technologies | $8.66
+6.0% | 10/11/2018 | C. Werther | Initiated Coverage | Buy | | View details for Dawson James rating of Adherex Technologies (NASDAQ:FENC) on 10/11/2018 |
LUNA Luna Innovations | $0.77
-9.4% | 10/2/2018 | B. Sine | Initiated Coverage | Buy | | View details for Dawson James rating of Luna Innovations (NASDAQ:LUNA) on 10/2/2018 |
VERU Veru | $3.60
+1.4% | 6/25/2018 | R. Wasserman | Reiterated Rating | Buy | | View details for Dawson James rating of Veru (NASDAQ:VERU) on 6/25/2018 |
LVO LiveOne | $0.60
+1.8% | 6/4/2018 | B. Sine | Reiterated Rating | Buy | | View details for Dawson James rating of LiveOne (NASDAQ:LVO) on 6/4/2018 |
ALT Altimmune | $3.54
+0.3% | 5/29/2018 | R. Wasserman | Reiterated Rating | Buy | | View details for Dawson James rating of Altimmune (NASDAQ:ALT) on 5/29/2018 |
CVM CEL-SCI | $9.52
+3.8% | 10/16/2017 | R. Wasserman | Reiterated Rating | Neutral | | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 10/16/2017 |
TNXP Tonix Pharmaceuticals | $37.98
+5.9% | 8/23/2017 | R. Wasserman | Reiterated Rating | Buy | $57,600,000.00 | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 8/23/2017 |
KURA Kura Oncology | $7.65
+2.8% | 8/8/2017 | R. Wasserman | Reiterated Rating | Buy | | View details for Dawson James rating of Kura Oncology (NASDAQ:KURA) on 8/8/2017 |
EPIX ESSA Pharma | $1.93
+0.5% | 8/3/2017 | R. Wasserman | Reiterated Rating | Buy | | View details for Dawson James rating of ESSA Pharma (NASDAQ:EPIX) on 8/3/2017 |
CVM CEL-SCI | $9.52
+3.8% | 3/11/2016 | R. Wasserman | Reiterated Rating | Buy | | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 3/11/2016 |
SLNO Soleno Therapeutics | $68.57
-1.8% | 5/6/2015 | - | Initiated Coverage | Buy | $952.50 | View details for Dawson James rating of Soleno Therapeutics (NASDAQ:SLNO) on 5/6/2015 |
CVM CEL-SCI | $9.52
+3.8% | 3/2/2015 | - | Initiated Coverage | Buy | $90.00 | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 3/2/2015 |
AXGN AxoGen | $16.26
+2.7% | 5/14/2014 | - | Initiated Coverage | Buy | $5.00 | View details for Dawson James rating of AxoGen (NASDAQ:AXGN) on 5/14/2014 |
NEO NeoGenomics | $6.61
+7.0% | 5/14/2014 | - | Initiated Coverage | Buy | $6.00 | View details for Dawson James rating of NeoGenomics (NASDAQ:NEO) on 5/14/2014 |
AGEN Agenus | $4.52
-1.1% | 3/12/2013 | - | Reiterated Rating | Buy | | View details for Dawson James rating of Agenus (NASDAQ:AGEN) on 3/12/2013 |
MD Pediatrix Medical Group | $16.97
+5.1% | 3/12/2013 | - | Downgrade | Buy -> Neutral | $80.00 | View details for Dawson James rating of Pediatrix Medical Group (NYSE:MD) on 3/12/2013 |
ARWR Arrowhead Pharmaceuticals | $21.33
+2.8% | 2/26/2013 | - | Initiated Coverage | Buy | $4.00 | View details for Dawson James rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 2/26/2013 |
ATOS Atossa Genetics | $0.78
+4.5% | 12/20/2012 | - | Initiated Coverage | Outperform | $120.00 | View details for Dawson James rating of Atossa Genetics (NASDAQ:ATOS) on 12/20/2012 |
BMY Bristol Myers Squibb | $47.84
-1.2% | 12/12/2012 | - | Reiterated Rating | Market Outperform | $51.00 | View details for Dawson James rating of Bristol Myers Squibb (NYSE:BMY) on 12/12/2012 |
AMGN Amgen | $293.72
-0.7% | 12/7/2012 | - | Initiated Coverage | Outperform | $91.00 | View details for Dawson James rating of Amgen (NASDAQ:AMGN) on 12/7/2012 |
GEO Geo Group | $21.36
+0.9% | 12/4/2012 | - | Downgrade | Market Perform | | View details for Dawson James rating of Geo Group (NYSE:GEO) on 12/4/2012 |
SRPT Sarepta Therapeutics | $20.22
+0.8% | 11/27/2012 | - | Initiated Coverage | Outperform | | View details for Dawson James rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/27/2012 |
RMTI Rockwell Medical | $1.14
-1.3% | 11/27/2012 | - | Initiated Coverage | Outperform | $132.00 | View details for Dawson James rating of Rockwell Medical (NASDAQ:RMTI) on 11/27/2012 |
AGEN Agenus | $4.52
-1.1% | 11/27/2012 | - | Initiated Coverage | Outperform | | View details for Dawson James rating of Agenus (NASDAQ:AGEN) on 11/27/2012 |
SLS SELLAS Life Sciences Group | $1.91
+8.5% | 11/27/2012 | - | Initiated Coverage | Outperform | $150.00 | View details for Dawson James rating of SELLAS Life Sciences Group (NASDAQ:SLS) on 11/27/2012 |
CYTK Cytokinetics | $38.34
+0.8% | 11/27/2012 | - | Downgrade | Outperform | | View details for Dawson James rating of Cytokinetics (NASDAQ:CYTK) on 11/27/2012 |
GALT Galectin Therapeutics | $4.10
+5.7% | 7/6/2012 | - | Lower Price Target | Buy | $3.00 | View details for Dawson James rating of Galectin Therapeutics (NASDAQ:GALT) on 7/6/2012 |
TNXP Tonix Pharmaceuticals | $37.98
+5.9% | 4/26/2012 | - | Initiated Coverage | Buy | $25,600,000.00 | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 4/26/2012 |
NFLX Netflix | $1,204.65
-0.1% | 10/28/2011 | - | Lower Price Target | Sell | $16.50 -> $7.14 | View details for Dawson James rating of Netflix (NASDAQ:NFLX) on 10/28/2011 |
IMUC EOM Pharmaceutical | $0.10
+6.8% | 3/22/2011 | - | Initiated Coverage | Buy | $5.00 | View details for Dawson James rating of EOM Pharmaceutical (OTCMKTS:IMUC) on 3/22/2011 |
MarketBeat All Access